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Detroit Expert Panel on the Assessment and Management of the Neuropsychiatric Symptoms of
Dementia
Noncognitive neuropsychiatric symptoms (NPS) of demen-
tia (aggression, agitation, depression, anxiety, delusions,
hallucinations, apathy, disinhibition) affect individuals
with dementia nearly universally across dementia stages
and etiologies. NPS are associated with poor outcomes for
individuals with dementia and caregivers, including excess
morbidity and mortality, greater healthcare use, and earlier
nursing home placement, as well as caregiver stress,
depression, and difficulty with employment. Although the
Food and Drug Administration has not approved pharma-
cotherapy for NPS, psychotropic medications are fre-
quently used to manage these symptoms, but in the few
cases of proven pharmacological efficacy, significant risk
of adverse effects may offset benefits. There is evidence of
efficacy and limited potential for adverse effects of non-
pharmacological treatments, typically considered first line,
but their uptake as preferred treatments remains inade-
quate in real-world clinical settings. Thus, the field cur-
rently finds itself in a predicament in terms of management
of these difficult symptoms. It was in this context that the
University of Michigan Program for Positive Aging, work-
ing in collaboration with the Johns Hopkins Alzheimer’s
Disease Research Center and Center for Innovative Care in
Aging sponsored and convened a multidisciplinary expert
panel in Detroit, Michigan, in fall 2011 with three objec-
tives: to define critical elements of care for NPS in demen-
tia; to construct an approach describing the sequential and
iterative steps of managing NPS in real-world clinical set-
tings that can be used as a basis for integrating nonphar-
macological and pharmacological approaches; and to
discuss how the approach generated could be implemented
in research and clinical care. J Am Geriatr Soc 62:762–
769, 2014.
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Although cognitive impairment is the clinical hallmarkof dementia, noncognitive neuropsychiatric symptoms
(NPS) are exceedingly common and dominate the presenta-
tion.1 NPS occur in all types of dementia in clusters or
syndromes identified as depression, psychosis, agitation,
aggression, apathy, sleep disturbances, and disinhibition.2
NPS are universal, affecting 98% of individuals at some
point in the disease course.2 Thirty percent of the cost of
caring for community-dwelling individuals with dementia
is directly attributable to NPS management.3 NPS appear
to be a consequence of the confluence of multiple, but
sometimes modifiable, interacting factors internal and
external to persons with dementia; are closely linked to
the underlying brain disease causing cognitive symptoms;
and result in part from heightened vulnerability to the
environment as cognitive ability declines.
Noncognitive neuropsychiatric symptoms, as opposed
to core cognitive symptoms, tend to create the most difficul-
ties for individuals with dementia, caregivers, and providers
and commonly lead to early nursing home placement,4,5
excess morbidity, mortality, hospital stays,6 caregiver stress
and depression, and reduced caregiver employment
income.7,8 These symptoms pose threats to caregivers’ own
health and quality of life.9 Caregivers of individuals with
NPS are more distressed and depressed than those not man-
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aging NPS.10 Clinically significant NPS, if untreated, are
associated with faster disease progression than in the
absence of such symptoms.11 Therefore, effective treatments
may have the potential to modify disease course, lower
costs, and improve quality of life for individuals with
dementia and caregivers.
In real-world settings, few well-proven treatment
options are currently available for NPS. Although there
are no Food and Drug Administration–approved medica-
tions for NPS, it is common clinical practice to use psy-
chotropic medications such as antipsychotics to control
symptoms, but antipsychotics show modest efficacy in
improving NPS1 and have significant risks including side
effects and mortality.12
Nonpharmacological management of NPS is increas-
ingly recognized as a critical part of comprehensive,
state-of-the-art dementia care.13,14 Nonpharmacological
approaches tend to conceptualize behaviors as stemming
from unmet needs, environmental overload, and
interactions of individual, caregiver, and environmental
factors. The goals of nonpharmacological treatment are
prevention, symptom relief, and reduction of caregiver dis-
tress.15 Multiple medical organizations and expert groups
(including the American Geriatrics Society, American Psy-
chiatric Society, and American Association for Geriatric
Psychiatry) recommend nonpharmacological strategies as
the preferred first-line treatment approach to NPS,16–19
except in emergency situations when NPS could lead to
imminent danger or otherwise compromise safety. In the
latter cases, the standard of care supports psychotropic use
in the absence of data. Unfortunately, effective nonphar-
macological strategies for NPS have not been translated
into real-world clinical management and standard care.20
Despite major concerns about safety and efficacy, psycho-
tropic drugs remain the primary treatment approach, often
without systematic assessment of potential underlying
causes.21
There are several reasons for the predominant use of
medications over nonpharmacological strategies. Most spe-
cialties have some training in psychotropic use for NPS, but
few receive instruction in nonpharmacological approaches
and are aware of their effectiveness.21 Even when aware of
these techniques and their value, most providers lack basic
training in assessing NPS and choosing or communicating
strategies to individuals with dementia and caregivers.
Assessing NPS and using nonpharmacological strategies can
be time-prohibitive and not reimbursed. Approaches devel-
oped in research trials22–25 typically circumvent provider
time limitations by training nonmedical personnel to deliver
interventions, and thus, strategies remain outside standard
clinical practices. Enhancing clinician decision-making for
NPS is timely and critical in view of a national movement to
improve dementia care,26 new American Medical Associa-
tion Pay-for-Performance Guidelines27 that will require phy-
sicians to evaluate and treat NPS as part of on-going
standard care, as well as Centers for Medicare and
Medicaid Services efforts to reduce unnecessary use of anti-
psychotics in nursing homes.28
Critically needed is an evidence-informed standardized
approach to managing NPS that integrates pharmacologi-
cal and nonpharmacological treatments for real-world
implementation. To address this, the University of
Michigan Program for Positive Aging, in collaboration
with the Johns Hopkins Alzheimer’s Disease Research
Center and Center for Innovative Care in Aging, sponsored
and convened a multidisciplinary expert panel in Detroit,
Michigan, in 2011. Panel members had clinical and
research expertise in managing NPS in dementia and
reducing distress in family caregivers. This article summa-
rizes the approach that the panel developed.
IMPORTANT CARE ELEMENTS FOR NPS
Treatments for NPS can be categorized as pharmacologi-
cal, medical, or nonpharmacologic (which the expert panel
referred to as “behavioral and environmental interven-
tions”). The nonpharmacological strategies underlying the
Describe, Investigate, Create, Evaluate (DICE) approach
are those with the strongest evidence base, including thor-
ough assessments for underlying causes and family care-
giver interventions.22–25,29–31 Members of the expert panel
discussed different decision-making approaches that had
common elements of identifying and treating NPS.18,32–35
This included the “4 D Approach,”13 an earlier step-wise
algorithm related to dementia behavior management that
served as the starting point from which the panel further
elaborated and relabeled steps to enhance clarity and ease
of use by clinicians and from which the mnemonic
“DICE” was developed.
THE DICE APPROACH
The DICE approach assumes that a problem NPS has been
identified and brought to the provider’s attention (Fig-
ure 1). To expand upon and detail each step of the
approach, the panel used a case example of an 80-year-old
woman with moderate dementia who strikes out at her
daughter during bathing. This case reflects a typical clini-
cal scenario often resulting in prescription of a psychotro-
pic and for which research supports behavioral and
environmental interventions.
Step 1. Describe
The first step (Table 1) is to describe the presenting behav-
ior to derive an accurate characterization of the NPS and
the context in which it occurs through discussion with
caregiver and individual with dementia (if possible).
Strategies for eliciting details include asking caregivers
to play back the NPS “as if in a movie.” A basic
problem-solving approach identifies antecedents, describes
the specifics of the NPS, and then details consequences to
uncover the context in which NPS occur and potential
underlying modifiable patterns or contributory factors.
Caregivers can be encouraged to record NPS and the
related patient, caregiver, and environmental consider-
ations (Table 1) in diaries or logs at home if possible.
Except in severe dementia, when communication may be
problematic, the perspective of the individual with demen-
tia should be elicited, and clinicians should probe to deter-
mine what he or she can describe about the NPS. It is
important to understand what aspect of the symptom is
most distressing or problematic for the individuals and
caregiver and the treatment goal. Eliciting this information
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helps to evaluate the caregiver’s knowledge of dementia
and NPS and leads to specific treatment strategies.
In the case example, the caregiver uses the term “agi-
tation,” yet this could encompass a range of symptoms
(anxiety, repetitive questions, aggression, wandering), each
of which might have a different underlying cause and
corresponding management strategy. The Describe step
reveals that “agitation” refers to the individual becoming
physically and verbally aggressive with the caregiver at
bath time. The individual expresses that bathing “hurts.”
(She experiences pain when the caregiver puts her in the
bath.) The caregiver indicates that, although she is not
afraid for her own safety, she believes the individual with
dementia is “doing this on purpose.” The caregiver’s goal
is to have the individual bathe daily. There are no symp-
toms to suggest psychosis, and the individual with demen-
tia does not have depressive symptoms.
Step 2. Investigate
Once the NPS is well characterized, the next step is for the
provider to examine, exclude, and identify possible under-
lying and modifiable causes (Table 1). Similar to the exam-
ination of delirium, the key to managing NPS is thorough
assessment of underlying causes. Undiagnosed medical
conditions are important contributors. Individuals with
dementia may have pain and undiagnosed illnesses (e.g.,
urinary tract infection, anemia) disproportionately more
than those without.29,36
Individual Considerations
This includes evaluating the current medication profile and
presence of undetected medical conditions or pain.
Compiling a list of medications, optimally by having the
caregiver bring in bottles, including prescription and over-
the-counter drugs and supplements, is an important first
measure. Providers should assess the contributions of
medication side effects, particularly those with anticholin-
ergic properties, as well as considering possible drug
interactions. Investigating medical conditions such as uri-
nary tract and other infections, constipation, dehydration,
and pain is critical. Obtaining blood work such as chemis-
try (e.g., blood glucose and electrolytes), complete blood
count with differential, and a urinalysis may be helpful.
Providers should also consider the effect of underlying
prior psychiatric comorbidity (e.g., lifelong major depres-
sive or anxiety disorder). Other important considerations
include limitations in functional abilities, severity of cogni-
tive impairment, poor sleep hygiene, sensory changes, and
boredom. Psychological factors including feelings of inade-
quacy and helplessness and fear of “being a burden” to
the family may play a role in the development and exacer-
bation of NPS.
Caregiver Considerations
These include understanding the historical and current
quality of the relationship between the individual and the
caregiver. Caregivers may lack an understanding of the
link between dementia and NPS and believe the individual
is “doing this to them on purpose.” Caregiver communica-
tion styles, expectations, over- and underestimation of the
individual’s abilities, and their own stress and depression
may inadvertently exacerbate behaviors. Finally, under-
standing the family cultural context is important. Beliefs
will affect the behaviors of the caregiver and the individual
with dementia differently. In some families, nursing home
placement may not be acceptable, and tremendous strain
may be created in attempting to keep a person with severe
limitations at home. In other families, discussing NPS may
be difficult and viewed as “airing dirty laundry” to
“outsiders.”
Describe
InvesƟgate
Create
Evaluate
Caregiver describes problemaƟc behavior
Context (who, what, when and where)
Social and physical environment
PaƟent perspecƟve
Degree of distress to paƟent and caregiver
Provider invesƟgates possible causes of problem behavior
PaƟent
MedicaƟon side eﬀects
Pain
FuncƟonal limitaƟons 
Medical condiƟons
Psychiatric comorbidity
Severity of cogniƟve impairment, execuƟve dysfuncƟon
Poor sleep hygiene
Sensory changes
Fear, sense of loss of control, boredom
Caregiver eﬀects/expectaƟons
Social and physical environment
Cultural factors
Provider, caregiver and team collaborate to create and 
implement treatment plan
Respond to physical problems
Strategize behavioral intervenƟons
Providing caregiver educaƟon and support
Enhancing communicaƟon with the paƟent
CreaƟng meaningful acƟviƟes for the paƟent
Simplifying tasks
Ensuring the environment is safe
Increasing or decreasing sƟmulaƟon in the environment
Provider evaluates whether “CREATE” intervenƟons have 
been implemented by caregiver and are safe and eﬀecƟve
The DICE Approach
ConsideraƟon of Psychotropic U
se (Acuity/Safety)
Figure 1. The DICE Approach.
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Environmental Considerations
An environment that is over- or understimulating or pre-
sents way-finding challenges and lack of predictable rou-
tines and pleasurable activities can also affect NPS.
Home safety is important; whether the individual can
easily leave home, has access to dangerous objects
(knives, guns), and can navigate safely from one room to
the next and whether there are grab bars and other
equipment and adaptations (e.g., labels, adequate task
lighting) that compensate for functional difficulties should
be considered.
In the case example, the provider learns that the individ-
ual with dementia has a diagnosis of arthritis but is not
taking pain medication. When the caregiver moves the
individual’s limbs quickly, it causes pain, which may
contribute to her aggression to stop it. The caregiver’s
Table 1. Linkage of DICE Steps with Patient/Caregiver/Environmental Considerations
DICE STEP Patient Considerations Caregiver Considerations Environmental Considerations
Describe
• What behavior did the
patient exhibit?
• How did the patient
perceive what occurred?
• How did the patient feel
about it?
• Is the patient’s safety at
risk?
• How much distress did the
behavior generate for
the caregiver?
• Does the caregiver feel their
safety is threatened by the
behavior?
• What about the behavior is
distressing to the caregiver?
• What did the caregiver do
during and after the behavior
occurred?
• Who was there when behavior occurred
(e.g. family members, unfamiliar people)?
• When did the behavior occur (time of day)
and what relationship did this have to other
events (e.g. occurring while bathing or at dinner)?
• Where did the behavior occur (e.g. home,
daycare, restaurant)?
• What happened before and after the behavior
occurred in the environment?
Investigate
Could the
behavior be
caused by/
contributed to by:
• Recent changes in
medications?
• Untreated or undertreated
pain?
• Limitations in functional
abilities?
• Medical conditions (e.g.
urinary tract infection)?
• Underlying psychiatric
comorbidity?
• Severity of cognitive
impairment, executive
dysfunction?
• Poor sleep hygiene?
• Sensory changes (vision,
hearing)?
• Fear, sense of loss of
control, boredom?
• Caregiver’s lack of
understanding of dementia
(e.g. patient is “doing this to”
them “on purpose”)?
• Caregiver’s negative
communication style (e.g.
overly critical or harsh, use of
complex questions, offering too
many choices)?
• Caregiver’s expectations not
aligned with dementia stage
(under or over estimation of
capability)?
• Caregiver’s own stress/
depression?
• Family/Cultural context (e.g.
not wanting to involve
“outsiders” or “air dirty laundry”,
promise to keep patient at
home)?
• Over- (e.g. clutter, noise, people) or under-
(e.g. lack of visual cues, poor lighting) stimulating
environment?
• Difficulty navigating or finding way in
environment?
• Lack of predictable daily routines that are
comforting to patient?
• Lack of pleasurable activities tapping into
preserved capabilities and previous interests?
Create Respond to physical
problems:
• Discontinue medications
causing behavioral side
effects if possible
• Manage pain
• Treat infections,
dehydration, constipation
• Optimize regimen for
underlying psychiatric
conditions
• Sleep hygiene measures
• Deal with sensory
impairments
Work collaboratively with caregiver/
other team members to institute
nonpharmacologic interventions
including (see Table 2 for detail):
• Providing caregiver education
and support
• Enhancing communication
with patient
• Creating meaningful activities
for patient
• Simplifying tasks
Work collaboratively with caregiver/other team
members to institute nonpharmacologic interventions
including (see Table 2 for detail):
• Ensuring the environment is safe
• Simplifying/enhancing the environment
Evaluate
• Has the intervention(s)
been effective for the
problem behavior?
• Have there been any
unintended consequences
or “side effects” from
the intervention(s)?
• Which interventions did the
caregiver implement?
• If the caregiver did not
implement the interventions,
why?
• What changes in the environment have been made?
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Table 2. Behavioral and Environmental Modification Strategies for Managing Noncognitive neuropsychiatric
symptoms
Domain Generalized Strategy (non-behavior specific)
Activity
• Tap into preserved capabilities and previous interests
• Encourage activities involving repetitive motion (folding towels, sorting buttons)
• Set up activity and help patient initiate participation
Caregiver education and support
• Convey that behaviors are not intentional
• Relax the rules (e.g. baths do not have to occur every day)
• Provide knowledge that with disease progression, patient will have difficulty
with executive function and completing tasks without guidance and cueing
• Avoid confrontation or trying to reason and convince
• Self-care; finding and taking opportunities for respite
• Identify and utilize a support network
Communication
• Allow patient sufficient time to respond to questions
• Provide 1- to 2-step simple verbal commands
• Use a calm, reassuring voice
• Offer simple choices (no more than 2 at a time)
• Avoid harsh tone and negative words
• Lightly touch to reassure, calm, direct or redirect
• Identify self/other for patients who are unable to remember names
• Help patient find words for self-expression
Environment • Remove clutter
• Use labeling and visual cues (e.g. arrows pointing to bathroom)
• Eliminate noise and distractions whenever possible
• Enhance environment if it is bland and lacking interest
Simplifying tasks
• Break tasks into simple steps
• Use verbal or tactile prompts at each step
• Create/provide structured daily routines that are predictable for patient
Examples of Specific Behavioral Targets Possible Targeted Strategies
Hearing voices
• Evaluate hearing or adjust amplification of hearing aids
• Assess quality and severity of symptoms
• Determine whether they present an actual threat to safety or function
Wandering/Elopement
• Identify triggers for elopement and modify them
• Notify neighbors and police of patient’s condition and potential for elopement
• Outfit with ID (e.g. Alzheimer’s Association Safe Return program)
Nighttime wakefulness
• Evaluate sleep routines and sleep hygeine
• Assess environment for possible contributions (e.g. temperature, noise, light,
shadows)
• Eliminate caffeine
• Create a structure that includes daily activity and exercise and a quiet routine
for bedtime (e.g. calming activity or music)
• Limit daytime napping
• Use a nightlight
• Nighttime respite for caregiver
Repetitive questioning
• Respond with a calm reassuring voice
• Use of calm touch for reassurance
• Inform patient of events only as they occur
• Structure with daily routines
• Use of distraction and meaningful activities
Aggression
• Determine and modify underlying cause of aggression (e.g. psychosis, pain,
particular caregiver interaction), evaluate triggers and patterns
• Warn caregiver not to confront or return physicality
• Discuss other self-protection strategies with caregiver (e.g. distract, backing away
from patient, leaving patient alone if they are safe, and seeking help)
• Limit access to or remove dangerous items
• Create a calmer, more soothing environment
ID = identification
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communication is also overly complex for the individual’s
dementia stage. The caregiver appears to lack an under-
standing of the link between dementia and behaviors (“she
is doing this on purpose”). The caregiver’s tone with the
individual when frustrated is harsh and confrontational (“I
can’t have you acting like this. I have to give you a bath
now!”). The caregiver’s goal to bathe the individual daily
reflects the caregiver’s own values and preferences and intent
to keep daily life as it was before dementia onset. The bath-
tub does not have a grab bar or bath mat, which may be con-
tributing to the fear of getting into and out of the tub.
Step 3. Create
In this step, the provider, caregiver, person with dementia
(if possible), and team collaborate to create and implement
a treatment plan (Table 1). The provider initially needs to
respond to physical problems detected in the investigate
step (prescribing antibiotics for a urinary tract infection,
giving fluids to a dehydrated individual, managing consti-
pation). This may also include discontinuing medications
that have the potential to cause behavioral side effects if
possible and evaluating whether other medication side
effects may be contributing to NPS. Effective pain manage-
ment also has an important role and can lead to reducing
unnecessary psychotropic prescriptions.37
For individuals with an underlying psychiatric condi-
tion predating the dementia (such as schizophrenia or
bipolar disorder), the psychotropic regimen for the disor-
der should be optimized with close monitoring and discon-
tinuation of medications that are ineffective or not
tolerated. Good sleep hygiene measures should be insti-
tuted. Sensory impairments (hearing, vision) should be
addressed.
This step requires creativity, with providers brain-
storming approaches with the caregiver, individual with
dementia (when possible), and other team members (visit-
ing nurse, social worker, occupational therapist). Brain-
storming with the caregiver is important to address an
active problem, to model problem-solving, and to obtain
buy-in for recommendations. Behavioral and environmen-
tal strategies deployed at this stage can be categorized as
generalized or targeted (Table 2). Generalized strategies
are not behavior specific and involve enriching the envi-
ronment and improving caregiver skills and well-being.
Targeted strategies are directed at eliminating a specific
NPS (e.g., aggression at bath time).15 Although there are
multiple potentially effective strategies depending upon
behavioral, individual, caregiver, and environmental con-
siderations, four domains of generalized strategies may be
most easily achievable and least labor intensive: providing
caregiver education, enhancing effective communication
between caregiver and individual with dementia, assisting
the caregiver in creating meaningful activities for the indi-
vidual with dementia, and helping the caregiver to simplify
tasks and establish structured routines. Additional prob-
lem-solving should occur concerning ensuring safety and
simplifying and enhancing the environment. Also, caregiv-
ers provide important information regarding what has
worked and what has not, interests of the person with
dementia, and a glimpse into lifelong personality and care
styles.
In the case example, the provider starts pain medica-
tion, makes a referral for physical therapy, and educates
the caregiver about dementia and that behaviors are not
intentional. The provider also suggests ways to improve
communication (calmer tones, simpler single-step com-
mands, light touch to reassure) and avoid negative interac-
tions (harsh tone, complex multistep commands, open-
ended questioning, screaming). Helping the caregiver
establish a “new normal” routine that promotes safety and
well-being, such as using sponge baths or bathing less fre-
quently and, when taking a bath, using a tub bench and
grab bar for safety is promoted.
Step 4. Evaluate
The final step is for the provider to assess whether recom-
mended strategies were attempted and effective. If the
caregiver did not implement an intervention, it is impor-
tant to understand why and brainstorm solutions. If an
intervention was attempted, it is important to evaluate
whether it was implemented effectively, whether the NPS
improved, and whether the caregiver’s distress was
reduced. The reaction of the individual with dementia to
the intervention(s) is important to assess, as are any unin-
tended side effects or consequences; a behavioral interven-
tion may make a behavior worse or have unintended
consequences. If so, the provider must understand whether
the negative outcome is a consequence of the intervention
or whether the intervention was not implemented as
intended. If psychotropic medications were judged to be
needed, it is important to consider a trial of dose reduction
or discontinuation to ensure that the medication continues
to be necessary. Because NPS change and fluctuate over
the course of dementia, ongoing monitoring of behaviors
is essential, and removal of interventions, especially medi-
cations, should be considered from time to time.
In the case example, several interventions addressing
pain (medication, physical therapy), caregiver education,
communication, personal preferences and values, and the
environment (bath safety measures) are suggested. The pro-
vider follows up with the caregiver regarding which were
deployed. If she chose not to deploy some, why? Of those
she did use, which were effective and judged helpful?
Psychotropic Medication Use
Given a mixed evidence-base for efficacy of most psycho-
tropics used for NPS,1,38 several in the expert panel group
were hesitant to recommend first-line treatment with medi-
cations under any circumstances. Others noted that lack of
homogeneity of NPS phenotype (e.g., trials of antipsychot-
ics for “agitation”) have plagued past trials and that medi-
cations might have greater efficacy with better attention to
such, but the current research is limited. Given the limita-
tions in the evidence-base, the panel consensus was that
psychotropic drugs should be used only after significant
efforts have been made to mitigate NPS using behavioral
and environmental modifications and medical interventions
if needed, with three exceptions. In each of these cases,
use would follow a concern regarding significant and
imminent risk: major depression with or without suicidal
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ideation, psychosis causing harm or with great potential of
harm, and aggression causing risk to self or others. The
panel also reinforced the need for close follow-up to moni-
tor for adverse effects potentially caused by psychotropic
medications and that use should be time-limited, because
behaviors and symptoms may resolve over time with or
without drug treatment. If providers elect to use psycho-
tropics, it is important to remember that there is no Food
and Drug Administration approval for their use in the
treatment of NPS and that the risk:benefit ratio of medica-
tion use must be carefully evaluated.
Psychotropic medications are not likely to affect
unfriendliness, poor self-care, memory problems, not pay-
ing attention or caring about what is going on, repetitive
verbalizations or questioning, rejection or refusal of care,
shadowing, and wandering.
Readers are referred to several articles for additional
information on the evidence base for and appropriate use
of psychotropic medications in dementia1,39,40 and for
additional information on the evidence base for nonphar-
macological interventions.15,31,41
RESEARCH AND CLINICAL CONSIDERATIONS
The Centers for Medicare and Medicaid Services has
reviewed the DICE approach since its development, and it
will be included in their toolkit to promote nonpharmaco-
logical approaches in dementia. Although the DICE
approach is evidence informed, it requires further research
testing in clinical settings. Content for each step may need
additional and better specification for use in specific settings
or by particular providers. The approach also has utility in
clinical trials of treatments for NPS, particularly in testing
new pharmacological agents. It can be used to better sub-
type NPS or focus on particular NPS at randomization cou-
pled with a systematic treatment approach (e.g., behavioral
or environmental intervention using the DICE method first,
followed by psychotropic testing). The new Medicare Pay-
for-Performance guidelines27 might compensate providers
for time spent in DICE or similar approaches. Because use
of DICE may result in fewer hospitalizations or readmis-
sions, it may be of interest to accountable care organiza-
tions. Application of this approach in social service agencies
involved with individuals with dementia deserves special
attention. Ultimately, developing technology applications of
DICE may simplify its use, save time, standardize its appli-
cation, and facilitate evaluation of its effectiveness.
CONCLUSIONS
Noncognitive neuropsychiatric symptoms are among the
most significant challenges in dementia care, yet they
remain under- or mistreated. Psychotropic medications are
currently the most commonly deployed management strat-
egies in real-world settings, but they often have suboptimal
risk:benefit profiles and may not affect some of the most
frequently occurring symptoms that are most distressing to
families and may trigger hospitalizations or nursing home
placement. Nonpharmacological techniques have a sub-
stantial evidence-base but are currently underused in
standard care. Innovative approaches that include training
and support of providers are needed to be able to serve
the burgeoning older population with neuropsychiatric
symptoms.42
The DICE approach offers clinicians an evidence-
informed structured approach that can be integrated into
diverse practice settings. The approach is inherently
individual- and caregiver-centered because concerns of
individuals with dementia and their caregivers are integral
to each step of the process. DICE enables clinicians to con-
sider conjointly the role of nonpharmacological, medical,
and pharmacological treatment; it offers a clinical reason-
ing approach through which clinicians can more efficiently
and effectively choose optimal treatment plans. The DICE
approach, endorsed by the Detroit Expert Panel, can
enhance clinical practice and outcomes and advance
research.
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